摘要
目的分析沐舒坦在儿科呼吸系统的临床应用价值。方法选择儿内科收治的呼吸系统疾病患儿,分为三组,对照组采用常规治疗,观察对比各组疗效。结果对照组与观察1组、观察2组咳痰、肺喘息、吸氧时间三组对比差异有统计学意义(P<0.05),观察2组咳痰、吸氧时间低于观察1组,差异有统计学意义(P<0.05)。结论联合雾化、口服沐舒坦辅助治疗儿科呼吸系统疾病疗效更好。
Objective To analyze the clinical value of Mucosolvan in pediatric respiratory system. MethodsChildren with respiratory diseases were selected and divided into three groups. The control group was treated with conventional therapy,and the curative effect of each group was observed and compared. Results There were significant differences between the control group and observation group 1 in observing the two groups of sputum expectoration,lung wheezing and oxygen inhalation time(P<0.05)The difference was statistically significant(P<0.05). Conclusion The combination of atomization and oral administration of mucosolvan is a better treatment for pediatric respiratory diseases.
出处
《大医生》
2017年第Z2期173-173,175,共2页
Doctor
关键词
儿科
呼吸系统
沐舒坦
pediatric
respiratory system
ambroxol
